<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2674</article-id>
         <article-id pub-id-type="publisher-id">2674</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Oncology</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Onkologija</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Professional article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Strokovni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Onkologija</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Celično-biološki mehanizmi delovanja amnijske membrane proti raku in možnosti za njeno uporabo pri zdravljenju raka</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Cell-biological mechanisms of amniotic membrane anticancer activity and the possibilities of its use in anticancer therapy</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Celično-biološki mehanizmi delovanja amnijske membrane proti raku</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Železnik Ramuta</surname>
                  <given-names>Taja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Cirman</surname>
                  <given-names>Tina</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Erdani Kreft</surname>
                  <given-names>Mateja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Zavod Republike Slovenije za transfuzijsko medicino, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Mateja Erdani Kreft, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>10</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>10</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>9–10</issue>
         <fpage>483</fpage>
         <lpage>92</lpage>
         <history>
            <date date-type="received">
               <day>23</day>
               <month>11</month>
               <year>2017</year>
            </date>
            <date date-type="accepted">
               <day>2</day>
               <month>3</month>
               <year>2018</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Izhodišče: Osnovna naloga amnijske membrane je zaščita ploda pred zunanjimi mehanskimi vplivi in izsušitvijo ter zagotavljanje primernega okolja za njegov razvoj. Razumevanje zgradbe in delovanja amnijske membrane je pomembno za njeno klinično uporabo, še posebej v regenerativni medicini. V prispevku opisujemo številne, za regenerativno medicino zelo zaželene mehanske in biološke lastnosti amnijske membrane ter predstavljamo njene protirakave lastnosti.</p>
            <p>Zaključek: Študije na modelih <italic>in vitro</italic> kot tudi študije na živalskih modelih dokazujejo, da amnijska membrana zavira proliferacijo rakavih celic in sproža njihovo apoptozo, deluje imunozaviralno, zavira energijsko presnovo rakavih celic in angiogenezo. Delo podaja pregled najnovejših spoznanj o protirakavem delovanju amnijske membrane in vrednoti njeno potencialno uporabo v zdravljenju raka in regenerativni medicini.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: The primary role of amniotic membrane is to protect the foetus from drying out and to provide a suitable environment for its development. Understanding of the structure and function of amniotic membrane is important in terms of its use in clinical settings, especially in regenerative medicine. This paper describes favourable mechanical and biological properties of amniotic membrane for regenerative medicine uses and emphasizes its anti-cancer properties.</p>
            <p>Conclusion: Studies on <italic>in </italic>
               <italic>vitro</italic> as well as on animal models demonstrate that amniotic membrane inhibits the proliferation of cancer cells and induces their apoptosis. It also acts immunoinhibitory, and it inhibits the metabolic activity of cancer cells and angiogenesis. This work provides an overview of the latest knowledge about the anticancer role of amniotic membrane and evaluates the potential of the amniotic membrane use for anticancer therapy and regenerative medicine.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>amnijska membrana</kwd>
            <kwd>rak</kwd>
            <kwd>protirakavo delovanje</kwd>
            <kwd>imunomodulacijsko delovanje</kwd>
            <kwd>regenerativna medicina</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>amniotic membrane</kwd>
            <kwd>cancer</kwd>
            <kwd>anticancer activity</kwd>
            <kwd>immunomodulatory activity</kwd>
            <kwd>regenerative medicine</kwd>
         </kwd-group>
         <custom-meta-group>
            <custom-meta>
               <meta-name>TotalReferences</meta-name>
               <meta-value>59</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesParsed</meta-name>
               <meta-value>56</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBillable</meta-name>
               <meta-value>57</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LinkServices</meta-name>
               <meta-value>pubmed-crossref</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinked</meta-name>
               <meta-value>55</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedDOI</meta-name>
               <meta-value>54</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedPMID</meta-name>
               <meta-value>51</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>JournalReferences</meta-name>
               <meta-value>53</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookReferences</meta-name>
               <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookChapterReferences</meta-name>
               <meta-value>1</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ConferenceReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ElectronicReferences</meta-name>
               <meta-value>1</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>DissertationReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LegalReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>StandardReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>OtherReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>UnknownReferences</meta-name>
               <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesSemiParsed</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBookUnparsed</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>EditorialStyle</meta-name>
               <meta-value>ICMJE-WHO</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Amnijska membrana (AM) je ekstraembrionalna ovojnica, ki obdaja s plodovnico napolnjeno votlino, v kateri se razvija plod (<xref ref-type="bibr" rid="b1">1</xref>). Sestavljajo jo enoskladni epitel amnijskih epitelnih celic, debela bazalna lamina in vezivno tkivo (tj. mezenhimski del AM, imenovan tudi stroma) (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b3">3</xref>). Iz amnijske membrane so osamili dve populaciji celic z lastnostmi matičnih celic, in sicer amnijske epitelne celice (AEC) in amnijske mezenhimske stromalne celice (AMSC) (<xref ref-type="fig" rid="fig1">Slika 1</xref>). Obe populaciji izražata površinske in znotrajcelične označevalce, značilne za matične celice (npr. SSEA-4, TRA1–60, TRA1–81, OCT-4 idr.) in se lahko diferencirata v različne tipe celic (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b5">5</xref>). Prednost AM je tudi v tem, da je njena uporaba etično sprejemljiva, saj posteljico in AM po porodu navadno zavržejo.</p>
         <fig position="anchor" id="fig1">
            <label>Slika 1:</label>
            <caption>
               <p> Molekularna in histološka zgradba amnijske membrane (AM). AM sestavljajo enoskladni epitel amnijskih epitelnih celic (AEC), bazalna lamina, amnijske mezenhimske stromalne celice (AMSC) in stroma AM, ki jo sestavljajo kompaktna plast, plast amnijskih mezenhimskih stromalnih celic in gobasta plast. Zunajcelični matriks AM sestavljajo različni kolageni in laminini, fibronektin, nidogen in proteoglikani.</p>
            </caption>
            <p>
               <graphic xlink:href="2674-web-resources/image/2674-1.jpg"/>
            </p>
         </fig>
         <p>Amnijska membrana ima številne lastnosti, zaradi katerih je primerna za klinično uporabo: a) zagotavlja zunajcelični matriks, ki omogoča pritrjanje in proliferacijo celic (<xref ref-type="bibr" rid="b6">6</xref>); b) spodbuja epitelizacijo in zavira brazgotinjenje (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b7">7</xref>-<xref ref-type="bibr" rid="b10">10</xref>); c) deluje protivnetno (<xref ref-type="bibr" rid="b11">11</xref>); č) ni imunogena (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b12">12</xref>); d) deluje angiogeno in protiangiogeno (<xref ref-type="bibr" rid="b13">13</xref>-<xref ref-type="bibr" rid="b15">15</xref>); e) deluje protimikrobno (<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>); f) sintetizira naravne inhibitorje metaloproteinaz (<xref ref-type="bibr" rid="b18">18</xref>)in g) deluje protirakavo (<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b20">20</xref>).</p>
         <p>Prvi dokumentirani primer uporabe AM v klinične namene sega v leto 1910, ko je Davis uporabil AM pri rekonstrukciji kože (<xref ref-type="bibr" rid="b21">21</xref>). Zdaj AM najpogosteje uporabljajo v oftalmologiji, predvsem pri rekonstrukcijah roženice in očesne veznice, saj spodbuja regeneracijo epitela in zavira vnetje ter brazgotinjenje (<xref ref-type="bibr" rid="b22">22</xref>). Poleg tega se AM uporablja tudi v dermatologiji za zdravljenje opeklin in kroničnih razjed (<xref ref-type="bibr" rid="b23">23</xref>) ter pri nekaterih kirurških postopkih, npr. pri preprečevanju adhezij po operaciji, v abdominalni kirurgiji pri preprečevanju peritonealnih adhezij (<xref ref-type="bibr" rid="b24">24</xref>) in zdravljenju gastroshize (<xref ref-type="bibr" rid="b25">25</xref>), pri operacijah rekonstrukcije vagine (<xref ref-type="bibr" rid="b26">26</xref>) in sečil (<xref ref-type="bibr" rid="b26">26</xref>-<xref ref-type="bibr" rid="b28">28</xref>).</p>
         <p>Rak je pri ljudeh drugi najpogostejši vzrok smrti. Kljub napredku pri preprečevanju in zdravljenju rakavih bolezni se število zbolelih za rakom zaradi povečevanja in staranja prebivalstva ter različnih dejavnikov tveganja (kajenje, debelost, prehrana, okoljski dejavniki) še vedno povečuje (<xref ref-type="bibr" rid="b29">29</xref>). Tumorji so kompleksni sistemi, ki poleg rakavih celic vključujejo tudi celice imunskega sistema, endotelne celice ter z rakom povezane fibroblaste (<italic>angl.</italic> cancer-associated fibroblasts, CAFs) (<xref ref-type="bibr" rid="b30">30</xref>). Hanahan in Weinberg sta v letih 2000 in 2011 opisala bistvene lastnosti rakavih celic: a) sposobnost neprestanih celičnih delitev, b) neodzivnost na signale, ki zavirajo celične delitve, c) izogibanje apoptozi, č) neskončen potencial za mitotske delitve, d) spodbujanje angiogeneze, e) invazivnost in metastaziranje, f) genomska nestabilnost, g) reprogramiranje celične energijske presnove, h) spodbujanje vnetja, i) izogibanje imunskemu sistemu (<xref ref-type="bibr" rid="b31">31</xref>,<xref ref-type="bibr" rid="b32">32</xref>).</p>
      </sec>
      <sec id="s2" sec-type="Amnijska membrana zavira proliferacijo rakavih celic">
         <label>2</label>
         <title>Amnijska membrana zavira proliferacijo rakavih celic</title>
         <p>Normalne, zdrave celice natančno nadzorujejo biosintezno pot in sproščanje signalnih molekul, ki spodbujajo njihovo rast ter jih vodijo v mitotsko delitev oz. zavirajo rast celic in preprečujejo njihov vstop v mitotsko delitev. S tem zagotavljajo vzdrževanje normalne tkivne arhitekture in funkcije. Rakave celice med razvojem pridobijo sposobnost izogibanja celičnim signalom, ki zavirajo celične delitve (<xref ref-type="bibr" rid="b32">32</xref>), zaradi česar pridobijo sposobnost neprestanih mitotskih delitev.</p>
         <p>Rast nekaterih rakavih celičnih linij hematopoetskega in nehematopoetskega izvora zavirajo AMSC. Pod vplivom AMSC se celični cikel rakavih celic ustavi v fazi G<sub>0</sub>/G<sub>1</sub>, saj AMSC povzročijo, da se v rakavih celicah zmanjša količina spodbujevalcev napredovanja celičnega cikla in poveča količina zaviralcev celičnega cikla. Zaviralni učinek AMSC na rakave celice so dokazali tako pri neposrednem stiku rakavih celic in AMSC v kokulturi, kot tudi v primeru, ko so bile celice fizično ločene in so bile AMSC nasajene na nosilce s porozno membrano, ki so bili vstavljeni v večprekatno petrijevko, rakave celice pa so bile nasajene na dno večprekatne petrijevke (<xref ref-type="bibr" rid="b33">33</xref>-<xref ref-type="bibr" rid="b35">35</xref>).</p>
         <p>Natančneje, v rakavih celicah se v prisotnosti AMSC zmanjša izražanje genov določenih ciklinov (ciklini D2/ E1/ H) in od ciklinov odvisnih kinaz (<italic>angl.</italic> cyclin-dependent kinase; Cdk2, Cdk4, Cdk6), ki spodbujajo napredovanje celičnega cikla. Zmanjšano je bilo tudi izražanje spodbujevalcev celičnega cikla, ki omogočajo napredovanje v fazi G<sub>1</sub>, mini kromosom vzdrževalnega kompleksa (<italic>angl</italic>
            <italic>.</italic> mini-chromosome maintenance complex; MCM2, MCM4, MCM5), proliferajočega celičnega jedrnega antigena (<italic>angl.</italic> proliferating cell nuclear antigen, PCNA) (<xref ref-type="bibr" rid="b33">33</xref>). Nasprotno pa je bilo povečano izražanje zaviralcev celičnega cikla, ki zavirajo napredovanje celičnega cikla (npr. inhibitorja od ciklinov odvisnih kinaz p21 in p15) in proteina pRb, ki zavira izražanje ciklinov A in E v fazi G<sub>0</sub>/G<sub>1</sub> (<xref ref-type="bibr" rid="b33">33</xref>,<xref ref-type="bibr" rid="b34">34</xref>). AMSC tako lahko ustavijo čezmerne mitotske delitve, ki so ena bistvenih lastnosti rakavih celic in zato pomembna tarča pri zdravljenju raka.</p>
      </sec>
      <sec id="s3" sec-type="Amnijska membrana spodbuja apoptozo rakavih celic">
         <label>3</label>
         <title>Amnijska membrana spodbuja apoptozo rakavih celic</title>
         <p>Apoptoza je programirana celična smrt, ki je naravna prepreka v razvoju raka. Ta se razvije kot posledica več genskih in kromosomskih mutacij, ki normalno celico spremenijo v rakavo, pri čemer je pridobitev sposobnosti za izogibanje apoptozi eden glavnih korakov karcinogeneze (<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b36">36</xref>).</p>
         <p>Pri gojenju rakavih celic v kokulturi z AEC ali pod vplivom kondicioniranega medija iz AM (tj. hranilnega medija, v katerem so gojili intaktno AM ali le celice iz AM) se v rakavih celicah poveča izražanje proapoptoznih proteinov (<xref ref-type="bibr" rid="b14">14</xref>) in značilno zmanjša preživetje teh celic (<xref ref-type="bibr" rid="b37">37</xref>). Jiao in sod. (<xref ref-type="bibr" rid="b38">38</xref>) so pri podganah dokazali, da AMSC zavirajo celično migracijo in da se zaradi apoptoze, ki jo AMSC sprožijo, zmanjša prostornino možganskih tumorjev gliomov za 30–50 % (<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b38">38</xref>) (<xref ref-type="fig" rid="fig2">Slika 2</xref>). Niknejad in sod. (2014) so dokazali, da kondicionirani medij iz AM zavira izražanje proteina toplotnega šoka Hsp90, kar sproži zaustavitev celičnega cikla in apoptozo ter zavre angiogenezo (<xref ref-type="fig" rid="fig2">Slika 2</xref>) (<xref ref-type="bibr" rid="b14">14</xref>).</p>
         <fig position="anchor" id="fig2">
            <label>Slika 2:</label>
            <caption>
               <p> Učinek amnijske membrane (AM) na lastnosti rakavih celic. a) lastnosti rakavih celic. b) protirakavo delovanje AM je rezultat različnih učinkov AM na rakave celice, in sicer AM zavira proliferacijo rakavih celic ter njihovo energijsko presnovo, deluje imunozaviralno, zavira angiogenezo in sproži apoptozo rakavih celic (povzeto po Hanahan in Weinberg, 2011 (<xref ref-type="bibr" rid="b32">32</xref>)). BDNF (možganski nevrotrofični dejavnik), CCL5 (kemokin CCL 5), COX-2 (ciklooksigenaza 2), CXCL-10 (kemokin CXCL-10), GCP-2 (granulocitni kemotaktični protein), GM-CSF (granulocitne in monocitne kolonije stimulirajoči dejavnik), HGF (hepatocitni rastni dejavnik), HSP90 (protein toplotnega šoka 90), IL-1/ -2/ -4/ -6/ -7/ -8/ -10 / -14/ -15/ -17 (interlevkin-1/ -2/ -4/ -6/ -7/ -8/ -10 / -14/ -15/ -17), IFNγ (interferon γ), MCM-2/ -4/ -5 (komponenta -2/ -4/ -5 vzdrževalnega kompleksa mini kromosoma), M-CSF (makrofagne kolonije stimulirajoči dejavnik), NT-3 (nevrotrofin-3), PCNA (proliferajoči celični jedrni antigen), PEDF (dejavnik pigmentnega epitela), TGFβ (transformirajoči rastni dejavnik β), TIMP 1/2/3/4 (tkivni ihibitor metaloproteinaze 1/2/3/4), TNF-α (tumor nekrotizirajoči dejavnik α), TSP-1 (trombospondin-1), VEGF (žilni endotelni rastni dejavnik).</p>
            </caption>
            <p>
               <graphic xlink:href="2674-web-resources/image/2674-2.png"/>
            </p>
         </fig>
         <p>Tudi proteinski izvleček AM, ki ga pripravijo s homogenizacijo in sonifikacijo AM, sproži apoptozo celic jetrnega karcinoma <italic>in vitro</italic> (celic HepG2, Hep3B2.1–8 in HuH7). Izvleček skoraj popolnoma zavre tudi rast tumorjev pri miših, inokuliranih s celicami HepG2, medtem ko ne zavre rasti tumorjev, inokuliranih s celicami HuH7. Avtorji predvidevajo, da je to povezano z močno povečanim izražanjem mutiranega proteina p53, ki zavira tumor v celicah HuH7, zaradi česar se te celice tudi slabše odzivajo na kemoterapijo z zdravili doksorubicin in paklitaksel (<xref ref-type="bibr" rid="b39">39</xref>,<xref ref-type="bibr" rid="b40">40</xref>) (<xref ref-type="fig" rid="fig2">Slika 2</xref>).</p>
         <p>Vzroki za zmanjšano preživetje rakavih celic pod vplivom AM so v citotoksičnih dejavnikih, ki jih izločajo AEC. Citotoksične dejavnike izločajo tudi AMSC (<xref ref-type="bibr" rid="b41">41</xref>) (<xref ref-type="fig" rid="fig2">Slika 2</xref>).</p>
         <p>Dosedanje raziskave kažejo, da AM lahko zaustavi proliferacijo rakavih celic ali celo sproži njihovo apoptozo (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b33">33</xref>,<xref ref-type="bibr" rid="b38">38</xref>,<xref ref-type="bibr" rid="b40">40</xref>). Razlike v delovanju AM so lahko posledica uporabe različnih delov AM (samo AMSC ali intaktna AM) in različnih rakavih celičnih linij (celične linije hematopoetskega in nehematopoetskega izvora, epitelne celice, jetrne celice). Ob možni uporabi AM pri zdravljenju raka se je zato treba zavedati, da se načini, s katerimi AM zavira rast ali sproži apoptozo rakavih celic, razlikujejo glede na tip celic in to tudi upoštevati pri načrtovanju klinične študije.</p>
      </sec>
      <sec id="s4" sec-type="Amnijska membrana vpliva na angiogenezo">
         <label>4</label>
         <title>Amnijska membrana vpliva na angiogenezo</title>
         <p>Zaradi svoje hitre rasti potrebujejo tumorji izdatnejši vir hranil in kisika ter intenzivnejše odvajanje presnovnih odpadkov in ogljikovega dioksida v primerjavi z normalnimi tkivi. Za preživetje tumorja je zato bistvena zmožnost razvoja žil – angiogeneza, na katero vpliva tudi AM.</p>
         <p>Intaktna AM z AEC onemogoča angiogenezo (<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b15">15</xref>). AEC namreč izločajo protiangiogene dejavnike, ki zavirajo nastajanje novih krvnih žil in s tem preprečujejo oskrbo tumorja s hranili ter kisikom. AM vsebuje tudi različne proteine zunajceličnega matriksa, npr. kolagen IV, fibronektin in kolagen VII, ki so vpleteni v zaviranje angiogeneze v roženici (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b15">15</xref>) (<xref ref-type="fig" rid="fig2">Slika 2</xref>). Če iz AM odstranimo AEC, prevladajo proangiogeni dejavniki, ki jih izločajo AMSC (<xref ref-type="fig" rid="fig2">Slika 2</xref>) (<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b42">42</xref>).</p>
         <p>Vse dosedanje študije kažejo, da AEC in proteini zunajceličnega matriksa AM zavirajo angiogenezo, medtem ko jo AMSC spodbujajo (<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b42">42</xref>).</p>
      </sec>
      <sec id="s5"
           sec-type="Amnijska membrana zmanjšuje energijsko presnovo rakavih celic">
         <label>5</label>
         <title>Amnijska membrana zmanjšuje energijsko presnovo rakavih celic</title>
         <p>Za nenadzorovano celično proliferacijo je nujna sprememba celične energijske presnove, ki omogoča rast in preživetje rakavih celic. V primerjavi z normalnimi (zdravimi) celicami, ki pridobivajo energijo predvsem z oksidativno fosforilacijo, rakave celice večinoma pridobivajo energijo z aerobno glikolizo (t. i. Warburgov učinek) (<xref ref-type="bibr" rid="b43">43</xref>). Takšne spremembe energijske presnove rakavim celicam omogočijo povečano tvorbo energije, zadostno biosintezo makromolekul in ohranjanje ravnovesja redoks ter s tem nastanek tumorjev (<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b44">44</xref>).</p>
         <p>Proteinski izvleček iz AM, pripravljen s homogenizacijo in sonikacijo AM, vpliva na presnovo rakavih celic (<xref ref-type="fig" rid="fig2">Slika 2</xref>). Mamede in sod. (2014) so dokazali, da proteinski izvleček iz AM zavira energijsko presnovno aktivnost pri 14 različnih celičnih linijah, pri petih celičnih linijah celo več kot 50 % presnovne aktivnosti (celične linije raka prostate PC3, raka črevesja WiDr, raka trebušne slinavke PANC-1, hepatokarcinoma HepG2 in Hep3B2.1–7) (<xref ref-type="bibr" rid="b45">45</xref>). Obenem so dokazali, da proteinski izvleček iz AM spodbuja presnovno aktivnost štirih drugih celičnih linij (celične linije raka debelega črevesja C2BBe1 in LS1034, raka dojke HCC1954, raka žolčevodov TFK-1), zato predvidevajo, da je odziv rakavih celic na AM specifičen glede na genetski profil oziroma tip rakave celice (<xref ref-type="bibr" rid="b40">40</xref>).</p>
      </sec>
      <sec id="s6"
           sec-type="Ali lahko imunozaviralno delovanje amnijske membrane izkoristimo v prid zdravljenju raka?">
         <label>6</label>
         <title>Ali lahko imunozaviralno delovanje amnijske membrane izkoristimo v prid zdravljenju raka?</title>
         <p>Vpliv imunskega sistema na rakave celice je predmet številnih raziskav, ki so pokazale, da lahko imunski sistem omogoči transformacijo normalnih celic v rakave celice, vpliva na imunogenost tumorja ter glede na stopnjo razvoja tumorja in njegovega mikrookolja prepreči ali nadzoruje rast tumorja (<xref ref-type="bibr" rid="b46">46</xref>). Tako npr. vnetje prispeva k razvoju tumorja, saj z njim pridejo v mikrookolje tumorja <italic>a)</italic> rastni dejavniki, ki spodbujajo delitve rakavih celic, <italic>b)</italic> proangiogeni dejavniki, <italic>c)</italic> encimi, ki modulirajo zunajcelični matriks in omogočajo angiogenezo, invazijo ter metastaziranje, č<italic>)</italic> signalne molekule, ki vodijo v aktiviranje epitelno-mezenhimskega prehoda in <italic>d)</italic> dejavniki, ki zavirajo apoptozo (<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b46">46</xref>). Poleg tega imunske celice izločajo reaktivne kisikove zvrsti, ki delujejo mutageno na sosednje celice (<xref ref-type="bibr" rid="b47">47</xref>).</p>
         <p>AM deluje imunozaviralno preko različnih signalnih poti. Celice AM zavirajo diferenciacijo monocitov v dendritične celice in s tem zmanjšajo njihovo sposobnost stimulacije limfocitov T. Celice AM namreč ustavijo monocite v fazi G<sub>0</sub> celičnega cikla in sintetizirajo IL-6, ki je vključen v zaviranje diferenciacije celic CD34+ in monocitov v dendritične celice (<xref ref-type="bibr" rid="b35">35</xref>) (<xref ref-type="fig" rid="fig2">Slika 2</xref>).</p>
         <p>Celice AM (AMSC in AEC) zavirajo proliferacijo enojedrnih celic iz periferne krvi (<italic>angl</italic>
            <italic>.</italic> peripheral blood mononuclear cell, PBMC) tako v kokulturi (celice so v neposrednem stiku) kot v sistemu, kjer so celice različnih tipov med seboj fizično ločene (na nosilcih s porozno membrano). Zaviralni učinek na proliferacijo PBMC pa ima tudi zgolj kondicionirani medij iz celic AM (<xref ref-type="fig" rid="fig2">Slika 2</xref>) (<xref ref-type="bibr" rid="b41">41</xref>,<xref ref-type="bibr" rid="b48">48</xref>-<xref ref-type="bibr" rid="b50">50</xref>).</p>
         <p>Različne študije kažejo, da rakave celice pogosto povečajo izločanje vnetnega kemokina IL-8 pri odzivu na kemoterapevtike ali druge stresne okoljske razmere (npr. hipoksijo) (<xref ref-type="bibr" rid="b51">51</xref>). S tem privabijo imunske celice v tumorsko mikrookolje in zato spodbudijo nastanek metastaz (<xref ref-type="bibr" rid="b52">52</xref>). Signalizacija IL-8 hkrati vpliva tudi na stimulacijo proliferacije (<xref ref-type="bibr" rid="b53">53</xref>), migracije, invazijo rakavih celic (<xref ref-type="bibr" rid="b54">54</xref>,<xref ref-type="bibr" rid="b55">55</xref>) in celo pomaga rakavim celicam, da se izognejo apoptozi (<xref ref-type="bibr" rid="b51">51</xref>,<xref ref-type="bibr" rid="b56">56</xref>). Magatti in sod. poročajo, da AEC in AMSC zavirajo izločanje IL-8 v kokulturi z dendritičnimi celicami (<xref ref-type="bibr" rid="b57">57</xref>). Predvidevamo, da tovrstni imunozaviralni učinek AM lahko z zaviranjem vnetja prispeva tudi k omejevanju razvoja tumorja.</p>
         <p>Po drugi strani lahko imunozaviralni učinek AM tudi omejuje imunski odziv, ki ščiti pred razvojem tumorjev. Naravne celice ubijalke zaradi svoje citolitične aktivnosti in sinteze vnetnih citokinov igrajo pomembno vlogo pri protivirusnem in protirakavem imunskem odzivu. Delovanje naravnih celic ubijalk močno uravnavajo receptorji na površini celic, saj je za lizo tarčne celice potrebno izražanje liganda/ligandov na površini tarčne celice, ki ga/jih prepozna receptor naravne celice ubijalke. AEC sintetizirajo inhibicijski dejavnik migracije (MMIF), ki je zaviralec migracije makrofagov in hkrati zaviralec z naravnimi celicami ubijalkami posredovane lize celic (<xref ref-type="bibr" rid="b49">49</xref>,<xref ref-type="bibr" rid="b58">58</xref>).</p>
         <p>Celice AM torej delujejo imunozaviralno, in sicer: <italic>a)</italic> celice AM so hipoimunogene in zavirajo tvorbo ter diferenciacijo antigen predstavitvenih celic, <italic>b</italic>
            <italic>)</italic> celice AM so sposobne modulacije fenotipa limfocitov T in imunskega odziva <italic>in vitro</italic>, predvsem pa so sposobne zaviranja alogene proliferacije limfocitov, <italic>c)</italic> celice AM zavirajo sintezo vnetnih citokinov ter povzročijo imunozaviralno delovanje lokalnega okolja (<xref ref-type="bibr" rid="b11">11</xref>). Prednost imunozaviralnega delovanja AM v mikrookolju tumorja je predvsem v tem, da na mestu vnosa AM ne pride do vnetja. S tem bi lahko preprečili dostop rastnih in proangiogenih dejavnikov ter encimov, ki bi modulirali zunajcelični matriks, v tumorsko mikrookolje in s tem onemogočili/omejili nadaljnji razvoj tumorja. V prihodnosti bodo vsekakor potrebne dodatne raziskave, ki bodo pokazale, ali lahko imunozaviralni učinek AM izkoristimo pri zdravljenju raka tudi v pogojih <italic>in vivo</italic>.</p>
      </sec>
      <sec id="s7" sec-type="Zaključek">
         <label>7</label>
         <title>Zaključek</title>
         <p>AM se zdaj najpogosteje uporablja v oftalmologiji in dermatologiji (<xref ref-type="bibr" rid="b26">26</xref>), hkrati pa narašča število študij, ki raziskujejo možnosti uporabe AM na drugih kliničnih področjih. Od leta 2002 je bilo v okviru ameriških Nacionalnih inštitutov za zdravje (National Institutes of Health, NIH) zaključenih 127 kliničnih študij, v katerih so preverjali možnost uporabe AM v kliniki, trenutno pa poteka 128 tovrstnih študij (<xref ref-type="bibr" rid="b59">59</xref>). Ker je področje uporabe AM pri potencialnem zdravljenju oziroma preprečevanju napredovanja rakavih bolezni sorazmerno novo področje, zaključenih kliničnih študij s tega področja še ni. Rezultati predkliničnih študij <italic>in vitro</italic> ter <italic>in vivo</italic> kažejo, da AM selektivno citotoksično deluje na različne tipe rakavih celic, medtem ko na normalne (zdrave) celice ne učinkuje. To je pomembno za potencialno uporabo AM pri zdravljenju raka, saj s tem zagotovimo, da zdravilo ne poškoduje zdravih celic. Trenutno na Univerzi v Miamiju v sodelovanju s podjetjem Vivex Biomedical izvajajo drugo fazo klinične študije (identifikacijska številka NCT02710422), za katero še evidentirajo bolnike s karcinomom prostate. V študiji bodo nevrovaskularni vozel, ki ostane po prostatektomiji, pokrili z dehidrirano AM, nato pa na vsake 3 mesece do 12 mesecev po operaciji merili raven prostatičnega specifičnega antigena (PSA) v krvi, ovrednotili uhajanje urina ter erektilno funkcijo preiskovancev. Študija se je začela maja 2016, trajala pa bo do aprila 2021. Študija je odprtega tipa, vanjo bo vključenih 280 bolnikov – 140 v kontrolno (placebo) skupino, 140 pa jih bo prejelo AM (<xref ref-type="bibr" rid="b59">59</xref>). Zagotovo bodo ta in prihodnje raziskave pomembno dopolnile naše znanje o protirakavem delovanju AM ter s tem morda še razširile nabor uporabe AM v terapevtske namene.</p>
      </sec>
      <sec id="s8" sec-type="Seznam kratic">
         <label>8</label>
         <title>Seznam kratic</title>
         <list>
            <list-item>
               <label>•</label>
               <p>AM – amnijska membrana</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>AMSC – amnijske mezenhimske stromalne celice</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>AEC – amnijske epitelne celice</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>BDNF – možganski nevrotrofični dejavnik (<italic>angl.</italic> brain-derived neurotrophic factor)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>CCL2/5/18 – kemokin CCL2/5/18 (<italic>angl</italic>
                  <italic>.</italic> chemokine (C-C motif) ligand 2/5/18)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>Cdk4/6 – od ciklinov odvisna kinaza 4/6 (<italic>angl.</italic> cyclin-dependent kinase 4/6)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>CXCL1/9/10 – kemokin CXCL1/9/10 (<italic>angl</italic>
                  <italic>.</italic> chemokine (C-X-C motif) ligand 1/9/10)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>COX-2 – ciklooksigenaza 2</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>GCP-2 – granulocitni kemotaktični protein (<italic>angl.</italic> granulocyte chemotactic protein 2)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>GM-CSF – granulocitne in monocitne kolonije stimulirajoči dejavnik (<italic>angl.</italic> granulocyte macrophage colony-stimulating factor)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>HSP90 – protein toplotnega šoka 90 (<italic>angl.</italic> heat shock protein 90)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>ICAM – intravaskularna adhezijska molekula (<italic>angl.</italic> Intravascular adhesion molecule)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>IL – interlevkin</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>IFNγ – interferon γ</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>M-CSF – makrofagne kolonije stimulirajoči dejavnik (<italic>angl</italic>
                  <italic>.</italic> macrophage colony-stimulating factor)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>MCM2, -4, -5 – komponenta 2/4/5 vzdrževalnega kompleksa mini kromosoma (<italic>angl</italic>
                  <italic>.</italic> mini-chromosome maitenance complex 2)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>MMIF – inhibicijski dejavnik migracije makrofagov (<italic>angl.</italic> macrophage migration inhibitory factor)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>PCNA – proliferajoči celični jedrni antigen (<italic>angl</italic>
                  <italic>.</italic> proliferating cell nuclear antigen)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>PEDF – dejavnik pigmentnega epitela (serpin F1 (SERPINF1)) (<italic>angl</italic>
                  <italic>.</italic> pigment epithelium-derived factor)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>PBMC – enojedrne celice iz periferne krvi (<italic>angl.</italic> peripheral blood mononuclear cells)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>PSA – prostatični specifični antigen (<italic>angl</italic>
                  <italic>.</italic> prostate specific antigen)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>TNFα – tumor nekrotizirajoči dejavnik α (<italic>angl</italic>
                  <italic>.</italic> tumor necrosis factor α)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>TGFβ – transformirajoči rastni dejavnik β (<italic>angl</italic>
                  <italic>.</italic> transforming growth factor β)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>TIMP 1/2/3/4 – tkivni inhibitor metaloproteinaze 1/2/3/4 (<italic>angl.</italic> tissue inhibitor of metalloproteinase 1/2/3/4)</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>TSP-1 – trombospondin-1</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>VEGF – žilni endotelni rastni dejavnik (<italic>angl</italic>
                  <italic>.</italic> vascular endothelial growth factor)</p>
            </list-item>
         </list>
      </sec>
   </body>
   <back>
      <ack>
         <label>9</label>
         <title>Zahvala</title>
         <p>Avtorji se iskreno zahvaljujemo Ginekološki kliniki Univerzitetnega kliničnega centra v Ljubljani in vsem porodnicam, ki so darovale amnijsko membrano v raziskovalne ali klinične namene. Najlepša hvala tudi Cvetani Tavzes za jezikovno redakcijo besedila. Delo je nastalo v okviru raziskovalnega programa št. P3–0108, projekta št. J4–7494 in projekta mladi raziskovalec, ki jih je sofinancirala Javna agencija za raziskovalno dejavnost Republike Slovenije iz državnega proračuna.</p>
      </ack>
      <ref-list>
         <ref id="b1">
            <mixed-citation publication-type="book" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hilmy</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Yusof</surname> 
                     <given-names>N</given-names>
                  </name>
               </person-group>. <source>Anatomy and Histology of Amnion. Human Amniotic Membrane</source>. <publisher-name>WORLD SCIENTIFIC</publisher-name>; <year>2017</year>. pp. <fpage>87</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1142/9789813226357_0005</pub-id>
            </mixed-citation>
         </ref>
         <ref id="b2">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Cirman</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Beltram</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Schollmayer</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Rožman</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Kreft</surname> 
                     <given-names>ME</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane properties and current practice of amniotic membrane use in ophthalmology in Slovenia</article-title>. <source>Cell Tissue Bank</source>. <year>2014</year> 
               <month>Jun</month>;<volume>15</volume>(<issue>2</issue>):<fpage>177</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/s10561-013-9417-6</pub-id>
               <pub-id pub-id-type="pmid">24352631</pub-id>
               <issn>1389-9333</issn>
            </mixed-citation>
         </ref>
         <ref id="b3">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Jerman</surname> 
                     <given-names>UD</given-names>
                  </name>, <name>
                     <surname>Veranič</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Kreft</surname> 
                     <given-names>ME</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane scaffolds enable the development of tissue-engineered urothelium with molecular and ultrastructural properties comparable to that of native urothelium</article-title>. <source>Tissue Eng Part C Methods</source>. <year>2014</year> 
               <month>Apr</month>;<volume>20</volume>(<issue>4</issue>):<fpage>317</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1089/ten.tec.2013.0298</pub-id>
               <pub-id pub-id-type="pmid">23947657</pub-id>
               <issn>1937-3384</issn>
            </mixed-citation>
         </ref>
         <ref id="b4">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Parolini</surname> 
                     <given-names>O</given-names>
                  </name>, <name>
                     <surname>Soncini</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Evangelista</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Schmidt</surname> 
                     <given-names>D</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine?</article-title> 
               <source>Regen Med</source>. <year>2009</year> 
               <month>Mar</month>;<volume>4</volume>(<issue>2</issue>):<fpage>275</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.2217/17460751.4.2.275</pub-id>
               <pub-id pub-id-type="pmid">19317646</pub-id>
               <issn>1746-0751</issn>
            </mixed-citation>
         </ref>
         <ref id="b5">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Caruso</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Evangelista</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Parolini</surname> 
                     <given-names>O</given-names>
                  </name>
               </person-group>. <article-title>Human term placental cells: phenotype, properties and new avenues in regenerative medicine</article-title>. <source>Int J Mol Cell Med</source>. <year>2012</year>;<volume>1</volume>(<issue>2</issue>):<fpage>64</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">24551761</pub-id>
               <issn>2251-9637</issn>
            </mixed-citation>
         </ref>
         <ref id="b6">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Cornwell</surname> 
                     <given-names>KG</given-names>
                  </name>, <name>
                     <surname>Landsman</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>James</surname> 
                     <given-names>KS</given-names>
                  </name>
               </person-group>. <article-title>Extracellular matrix biomaterials for soft tissue repair</article-title>. <source>Clin Podiatr Med Surg</source>. <year>2009</year> 
               <month>Oct</month>;<volume>26</volume>(<issue>4</issue>):<fpage>507</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.cpm.2009.08.001</pub-id>
               <pub-id pub-id-type="pmid">19778685</pub-id>
               <issn>0891-8422</issn>
            </mixed-citation>
         </ref>
         <ref id="b7">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Koizumi</surname> 
                     <given-names>NJ</given-names>
                  </name>, <name>
                     <surname>Inatomi</surname> 
                     <given-names>TJ</given-names>
                  </name>, <name>
                     <surname>Sotozono</surname> 
                     <given-names>CJ</given-names>
                  </name>, <name>
                     <surname>Fullwood</surname> 
                     <given-names>NJ</given-names>
                  </name>, <name>
                     <surname>Quantock</surname> 
                     <given-names>AJ</given-names>
                  </name>, <name>
                     <surname>Kinoshita</surname> 
                     <given-names>S</given-names>
                  </name>
               </person-group>. <article-title>Growth factor mRNA and protein in preserved human amniotic membrane</article-title>. <source>Curr Eye Res</source>. <year>2000</year> 
               <month>Mar</month>;<volume>20</volume>(<issue>3</issue>):<fpage>173</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1076/0271-3683(200003)2031-9FT173</pub-id>
               <pub-id pub-id-type="pmid">10694891</pub-id>
               <issn>0271-3683</issn>
            </mixed-citation>
         </ref>
         <ref id="b8">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Fukuda</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Chikama</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Nakamura</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Nishida</surname> 
                     <given-names>T</given-names>
                  </name>
               </person-group>. <article-title>Differential distribution of subchains of the basement membrane components type IV collagen and laminin among the amniotic membrane, cornea, and conjunctiva</article-title>. <source>Cornea</source>. <year>1999</year> 
               <month>Jan</month>;<volume>18</volume>(<issue>1</issue>):<fpage>73</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00003226-199901000-00013</pub-id>
               <pub-id pub-id-type="pmid">9894941</pub-id>
               <issn>0277-3740</issn>
            </mixed-citation>
         </ref>
         <ref id="b9">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Kim</surname> 
                     <given-names>JS</given-names>
                  </name>, <name>
                     <surname>Kim</surname> 
                     <given-names>JC</given-names>
                  </name>, <name>
                     <surname>Na</surname> 
                     <given-names>BK</given-names>
                  </name>, <name>
                     <surname>Jeong</surname> 
                     <given-names>JM</given-names>
                  </name>, <name>
                     <surname>Song</surname> 
                     <given-names>CY</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn</article-title>. <source>Exp Eye Res</source>. <year>2000</year> 
               <month>Mar</month>;<volume>70</volume>(<issue>3</issue>):<fpage>329</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1006/exer.1999.0794</pub-id>
               <pub-id pub-id-type="pmid">10712819</pub-id>
               <issn>0014-4835</issn>
            </mixed-citation>
         </ref>
         <ref id="b10">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Jerman</surname> 
                     <given-names>UD</given-names>
                  </name>, <name>
                     <surname>Kreft</surname> 
                     <given-names>ME</given-names>
                  </name>, <name>
                     <surname>Veranič</surname> 
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Epithelial-Mesenchymal Interactions in Urinary Bladder and Small Intestine and How to Apply Them in Tissue Engineering</article-title>. <source>Tissue Eng Part B Rev</source>. <year>2015</year> 
               <month>Dec</month>;<volume>21</volume>(<issue>6</issue>):<fpage>521</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1089/ten.teb.2014.0678</pub-id>
               <pub-id pub-id-type="pmid">26066408</pub-id>
               <issn>1937-3368</issn>
            </mixed-citation>
         </ref>
         <ref id="b11">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Insausti</surname> 
                     <given-names>CL</given-names>
                  </name>, <name>
                     <surname>Blanquer</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>García-Hernández</surname> 
                     <given-names>AM</given-names>
                  </name>, <name>
                     <surname>Castellanos</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Moraleda</surname> 
                     <given-names>JM</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane-derived stem cells: immunomodulatory properties and potential clinical application</article-title>. <source>Stem Cells Cloning</source>. <year>2014</year> 
               <month>Mar</month>;<volume>7</volume>:<fpage>53</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.2147/SCCAA.S58696</pub-id>
               <pub-id pub-id-type="pmid">24744610</pub-id>
               <issn>1178-6957</issn>
            </mixed-citation>
         </ref>
         <ref id="b12">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Szekeres-Bartho</surname> 
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Immunological relationship between the mother and the fetus</article-title>. <source>Int Rev Immunol</source>. <year>2002</year> 
               <month>Nov-Dec</month>;<volume>21</volume>(<issue>6</issue>):<fpage>471</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1080/08830180215017</pub-id>
               <pub-id pub-id-type="pmid">12650238</pub-id>
               <issn>0883-0185</issn>
            </mixed-citation>
         </ref>
         <ref id="b13">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Koob</surname> 
                     <given-names>TJ</given-names>
                  </name>, <name>
                     <surname>Lim</surname> 
                     <given-names>JJ</given-names>
                  </name>, <name>
                     <surname>Massee</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Zabek</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Denozière</surname> 
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>Properties of dehydrated human amnion/chorion composite grafts: implications for wound repair and soft tissue regeneration</article-title>. <source>J Biomed Mater Res B Appl Biomater</source>. <year>2014</year> 
               <month>Aug</month>;<volume>102</volume>(<issue>6</issue>):<fpage>1353</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.b.33141</pub-id>
               <pub-id pub-id-type="pmid">24664953</pub-id>
               <issn>1552-4973</issn>
            </mixed-citation>
         </ref>
         <ref id="b14">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Niknejad</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Khayat-Khoei</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Peirovi</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Abolghasemi</surname> 
                     <given-names>H</given-names>
                  </name>
               </person-group>. <article-title>Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy</article-title>. <source>Cytotherapy</source>. <year>2014</year> 
               <month>Jan</month>;<volume>16</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcyt.2013.07.005</pub-id>
               <pub-id pub-id-type="pmid">24113429</pub-id>
               <issn>1465-3249</issn>
            </mixed-citation>
         </ref>
         <ref id="b15">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Niknejad</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Paeini-Vayghan</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Tehrani</surname> 
                     <given-names>FA</given-names>
                  </name>, <name>
                     <surname>Khayat-Khoei</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Peirovi</surname> 
                     <given-names>H</given-names>
                  </name>
               </person-group>. <article-title>Side dependent effects of the human amnion on angiogenesis</article-title>. <source>Placenta</source>. <year>2013</year> 
               <month>Apr</month>;<volume>34</volume>(<issue>4</issue>):<fpage>340</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2013.02.001</pub-id>
               <pub-id pub-id-type="pmid">23465536</pub-id>
               <issn>0143-4004</issn>
            </mixed-citation>
         </ref>
         <ref id="b16">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>King</surname> 
                     <given-names>AE</given-names>
                  </name>, <name>
                     <surname>Paltoo</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Kelly</surname> 
                     <given-names>RW</given-names>
                  </name>, <name>
                     <surname>Sallenave</surname> 
                     <given-names>JM</given-names>
                  </name>, <name>
                     <surname>Bocking</surname> 
                     <given-names>AD</given-names>
                  </name>, <name>
                     <surname>Challis</surname> 
                     <given-names>JR</given-names>
                  </name>
               </person-group>. <article-title>Expression of natural antimicrobials by human placenta and fetal membranes</article-title>. <source>Placenta</source>. <year>2007</year> 
               <month>Feb-Mar</month>;<volume>28</volume>(<issue>2-3</issue>):<fpage>161</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2006.01.006</pub-id>
               <pub-id pub-id-type="pmid">16513165</pub-id>
               <issn>0143-4004</issn>
            </mixed-citation>
         </ref>
         <ref id="b17">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Kjaergaard</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Hein</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Hyttel</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Helmig</surname> 
                     <given-names>RB</given-names>
                  </name>, <name>
                     <surname>Schønheyder</surname> 
                     <given-names>HC</given-names>
                  </name>, <name>
                     <surname>Uldbjerg</surname> 
                     <given-names>N</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Antibacterial properties of human amnion and chorion in vitro</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2001</year> 
               <month>Feb</month>;<volume>94</volume>(<issue>2</issue>):<fpage>224</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0301-2115(00)00345-6</pub-id>
               <pub-id pub-id-type="pmid">11165729</pub-id>
               <issn>0301-2115</issn>
            </mixed-citation>
         </ref>
         <ref id="b18">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hao</surname> 
                     <given-names>Y</given-names>
                  </name>, <name>
                     <surname>Ma</surname> 
                     <given-names>DH</given-names>
                  </name>, <name>
                     <surname>Hwang</surname> 
                     <given-names>DG</given-names>
                  </name>, <name>
                     <surname>Kim</surname> 
                     <given-names>WS</given-names>
                  </name>, <name>
                     <surname>Zhang</surname> 
                     <given-names>F</given-names>
                  </name>
               </person-group>. <article-title>Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane</article-title>. <source>Cornea</source>. <year>2000</year> 
               <month>May</month>;<volume>19</volume>(<issue>3</issue>):<fpage>348</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1097/00003226-200005000-00018</pub-id>
               <pub-id pub-id-type="pmid">10832697</pub-id>
               <issn>0277-3740</issn>
            </mixed-citation>
         </ref>
         <ref id="b19">
            <mixed-citation publication-type="book" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Rocha</surname> 
                     <given-names>SC</given-names>
                  </name>, <name>
                     <surname>Baptista</surname> 
                     <given-names>CJ</given-names>
                  </name>
               </person-group>. <source>Biochemical Properties of Amniotic Membrane. V: Mamede AC, Botelho MF, ur. Amniotic Membrane</source>. <publisher-loc>Netherlands</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2015</year>. pp. <fpage>19</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/978-94-017-9975-1_2</pub-id>
            </mixed-citation>
         </ref>
         <ref id="b20">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Niknejad</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Yazdanpanah</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Mirmasoumi</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Abolghasemi</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Peirovi</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Ahmadiani</surname> 
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Inhibition of HSP90 could be possible mechanism for anti-cancer property of amniotic membrane</article-title>. <source>Med Hypotheses</source>. <year>2013</year> 
               <month>Nov</month>;<volume>81</volume>(<issue>5</issue>):<fpage>862</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2013.08.018</pub-id>
               <pub-id pub-id-type="pmid">24054818</pub-id>
               <issn>0306-9877</issn>
            </mixed-citation>
         </ref>
         <ref id="b21">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Davis</surname> 
                     <given-names>JW</given-names>
                  </name>
               </person-group>. <article-title>Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital</article-title>. <source>Johns Hopkins Med J</source>. <year>1910</year>;<volume>15</volume>:<fpage>87</fpage>.<issn>0021-7263</issn>
            </mixed-citation>
         </ref>
         <ref id="b22">
            <mixed-citation publication-type="book-chapter" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Costa</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Murta</surname> 
                     <given-names>JN</given-names>
                  </name>
               </person-group>. <chapter-title>Amniotic Membrane in Ophthalmology</chapter-title>. In: <person-group person-group-type="editor">
                  <name>
                     <surname>Mamede</surname> 
                     <given-names>AC</given-names>
                  </name>, <name>
                     <surname>Botelho</surname> 
                     <given-names>MF</given-names>
                  </name>, <role>editors</role>
               </person-group>. <source>Amniotic Membrane: Origin, Characterization and Medical Applications</source>. <publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name>; <year>2015</year>. pp. <fpage>105</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/978-94-017-9975-1_6</pub-id>
            </mixed-citation>
         </ref>
         <ref id="b23">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lo</surname> 
                     <given-names>V</given-names>
                  </name>, <name>
                     <surname>Pope</surname> 
                     <given-names>E</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane use in dermatology</article-title>. <source>Int J Dermatol</source>. <year>2009</year> 
               <month>Sep</month>;<volume>48</volume>(<issue>9</issue>):<fpage>935</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-4632.2009.04173.x</pub-id>
               <pub-id pub-id-type="pmid">19702975</pub-id>
               <issn>0011-9059</issn>
            </mixed-citation>
         </ref>
         <ref id="b24">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Kubanyi</surname> 
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Prevention of peritoneal adhesions by transplantation of amnion</article-title>. <source>BMJ</source>. <year>1947</year> 
               <month>Jul</month>;<volume>2</volume>(<issue>4514</issue>):<fpage>55</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.2.4514.55-a</pub-id>
               <pub-id pub-id-type="pmid">20344011</pub-id>
               <issn>0007-1447</issn>
            </mixed-citation>
         </ref>
         <ref id="b25">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Gharib</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Ure</surname> 
                     <given-names>BM</given-names>
                  </name>, <name>
                     <surname>Klose</surname> 
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Use of amniotic grafts in the repair of gastroschisis</article-title>. <source>Pediatr Surg Int</source>. <year>1996</year> 
               <month>Mar</month>;<volume>11</volume>(<issue>2-3</issue>):<fpage>96</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/BF00183734</pub-id>
               <pub-id pub-id-type="pmid">24057525</pub-id>
               <issn>0179-0358</issn>
            </mixed-citation>
         </ref>
         <ref id="b26">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Silini</surname> 
                     <given-names>AR</given-names>
                  </name>, <name>
                     <surname>Cargnoni</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Magatti</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Pianta</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Parolini</surname> 
                     <given-names>O</given-names>
                  </name>
               </person-group>. <article-title>The Long Path of Human Placenta, and Its Derivatives, in Regenerative Medicine</article-title>. <source>Front Bioeng Biotechnol</source>. <year>2015</year> 
               <month>Oct</month>;<volume>3</volume>:<fpage>162</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2015.00162</pub-id>
               <pub-id pub-id-type="pmid">26539433</pub-id>
               <issn>2296-4185</issn>
            </mixed-citation>
         </ref>
         <ref id="b27">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Koziak</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Salagierski</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Marcheluk</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Szcześniewski</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Sosnowski</surname> 
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Early experience in reconstruction of long ureteral strictures with allogenic amniotic membrane</article-title>. <source>Int J Urol</source>. <year>2007</year> 
               <month>Jul</month>;<volume>14</volume>(<issue>7</issue>):<fpage>607</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1111/j.1442-2042.2007.01781.x</pub-id>
               <pub-id pub-id-type="pmid">17645603</pub-id>
               <issn>0919-8172</issn>
            </mixed-citation>
         </ref>
         <ref id="b28">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Iijima</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Igawa</surname> 
                     <given-names>Y</given-names>
                  </name>, <name>
                     <surname>Imamura</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Moriizumi</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Nikaido</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Konishi</surname> 
                     <given-names>I</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Transplantation of preserved human amniotic membrane for bladder augmentation in rats</article-title>. <source>Tissue Eng</source>. <year>2007</year> 
               <month>Mar</month>;<volume>13</volume>(<issue>3</issue>):<fpage>513</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1089/ten.2006.0170</pub-id>
               <pub-id pub-id-type="pmid">17518600</pub-id>
               <issn>1076-3279</issn>
            </mixed-citation>
         </ref>
         <ref id="b29">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Fitzmaurice</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Dicker</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Pain</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Hamavid</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Moradi-Lakeh</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>MacIntyre</surname> 
                     <given-names>MF</given-names>
                  </name>, <etal>et al.</etal>; <collab>Global Burden of Disease Cancer Collaboration</collab>
               </person-group>. <article-title>The Global Burden of Cancer 2013</article-title>. <source>JAMA Oncol</source>. <year>2015</year> 
               <month>Jul</month>;<volume>1</volume>(<issue>4</issue>):<fpage>505</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.0735</pub-id>
               <pub-id pub-id-type="pmid">26181261</pub-id>
               <issn>2374-2437</issn>
            </mixed-citation>
         </ref>
         <ref id="b30">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Shiga</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Hara</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Nagasaki</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Sato</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Takahashi</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Takeyama</surname> 
                     <given-names>H</given-names>
                  </name>
               </person-group>. <article-title>Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth</article-title>. <source>Cancers (Basel)</source>. <year>2015</year> 
               <month>Dec</month>;<volume>7</volume>(<issue>4</issue>):<fpage>2443</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.3390/cancers7040902</pub-id>
               <pub-id pub-id-type="pmid">26690480</pub-id>
               <issn>2072-6694</issn>
            </mixed-citation>
         </ref>
         <ref id="b31">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hanahan</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Weinberg</surname> 
                     <given-names>RA</given-names>
                  </name>
               </person-group>. <article-title>The hallmarks of cancer</article-title>. <source>Cell</source>. <year>2000</year> 
               <month>Jan</month>;<volume>100</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id>
               <pub-id pub-id-type="pmid">10647931</pub-id>
               <issn>0092-8674</issn>
            </mixed-citation>
         </ref>
         <ref id="b32">
            <mixed-citation publication-type="unknown" specific-use="linked">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hanahan</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Weinberg</surname> 
                     <given-names>RA</given-names>
                  </name>
               </person-group>. <article-title>Hallmarks of cancer: the next generation.</article-title> Cell. <year>2011</year>;144(5):646:74. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
            </mixed-citation>
         </ref>
         <ref id="b33">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Magatti</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>De Munari</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Vertua</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Parolini</surname> 
                     <given-names>O</given-names>
                  </name>
               </person-group>. <article-title>Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest</article-title>. <source>J Cell Mol Med</source>. <year>2012</year> 
               <month>Sep</month>;<volume>16</volume>(<issue>9</issue>):<fpage>2208</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2012.01531.x</pub-id>
               <pub-id pub-id-type="pmid">22260183</pub-id>
               <issn>1582-1838</issn>
            </mixed-citation>
         </ref>
         <ref id="b34">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Malumbres</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Barbacid</surname> 
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Cell cycle, CDKs and cancer: a changing paradigm</article-title>. <source>Nat Rev Cancer</source>. <year>2009</year> 
               <month>Mar</month>;<volume>9</volume>(<issue>3</issue>):<fpage>153</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2602</pub-id>
               <pub-id pub-id-type="pmid">19238148</pub-id>
               <issn>1474-175X</issn>
            </mixed-citation>
         </ref>
         <ref id="b35">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Magatti</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>De Munari</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Vertua</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Nassauto</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Albertini</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Wengler</surname> 
                     <given-names>GS</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes</article-title>. <source>Cell Transplant</source>. <year>2009</year>;<volume>18</volume>(<issue>8</issue>):<fpage>899</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.3727/096368909X471314</pub-id>
               <pub-id pub-id-type="pmid">19523334</pub-id>
               <issn>0963-6897</issn>
            </mixed-citation>
         </ref>
         <ref id="b36">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Wong</surname> 
                     <given-names>RS</given-names>
                  </name>
               </person-group>. <article-title>Apoptosis in cancer: from pathogenesis to treatment</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2011</year> 
               <month>Sep</month>;<volume>30</volume>(<issue>1</issue>):<fpage>87</fpage>. <pub-id pub-id-type="doi">10.1186/1756-9966-30-87</pub-id>
               <pub-id pub-id-type="pmid">21943236</pub-id>
               <issn>0392-9078</issn>
            </mixed-citation>
         </ref>
         <ref id="b37">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>McIlwain</surname> 
                     <given-names>DR</given-names>
                  </name>, <name>
                     <surname>Berger</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Mak</surname> 
                     <given-names>TW</given-names>
                  </name>
               </person-group>. <article-title>Caspase functions in cell death and disease</article-title>. <source>Cold Spring Harb Perspect Biol</source>. <year>2013</year> 
               <month>Apr</month>;<volume>5</volume>(<issue>4</issue>):<fpage>a008656</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a008656</pub-id>
               <pub-id pub-id-type="pmid">23545416</pub-id>
               <issn>1943-0264</issn>
            </mixed-citation>
         </ref>
         <ref id="b38">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Jiao</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Guan</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Yang</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Li</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Song</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Hu</surname> 
                     <given-names>X</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo through the Bcl-2/caspase pathways</article-title>. <source>Mol Biol Rep</source>. <year>2012</year> 
               <month>Jan</month>;<volume>39</volume>(<issue>1</issue>):<fpage>467</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-011-0760-z</pub-id>
               <pub-id pub-id-type="pmid">21556762</pub-id>
               <issn>0301-4851</issn>
            </mixed-citation>
         </ref>
         <ref id="b39">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Chan</surname> 
                     <given-names>KT</given-names>
                  </name>, <name>
                     <surname>Lung</surname> 
                     <given-names>ML</given-names>
                  </name>
               </person-group>. <article-title>Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2004</year> 
               <month>Jun</month>;<volume>53</volume>(<issue>6</issue>):<fpage>519</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-004-0767-4</pub-id>
               <pub-id pub-id-type="pmid">15004724</pub-id>
               <issn>0344-5704</issn>
            </mixed-citation>
         </ref>
         <ref id="b40">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Mamede</surname> 
                     <given-names>AC</given-names>
                  </name>, <name>
                     <surname>Guerra</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Laranjo</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Carvalho</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Oliveira</surname> 
                     <given-names>RC</given-names>
                  </name>, <name>
                     <surname>Gonçalves</surname> 
                     <given-names>AC</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma</article-title>. <source>Med Oncol</source>. <year>2015</year> 
               <month>Dec</month>;<volume>32</volume>(<issue>12</issue>):<fpage>257</fpage>. <pub-id pub-id-type="doi">10.1007/s12032-015-0702-z</pub-id>
               <pub-id pub-id-type="pmid">26507652</pub-id>
               <issn>1357-0560</issn>
            </mixed-citation>
         </ref>
         <ref id="b41">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Kang</surname> 
                     <given-names>NH</given-names>
                  </name>, <name>
                     <surname>Hwang</surname> 
                     <given-names>KA</given-names>
                  </name>, <name>
                     <surname>Kim</surname> 
                     <given-names>SU</given-names>
                  </name>, <name>
                     <surname>Kim</surname> 
                     <given-names>YB</given-names>
                  </name>, <name>
                     <surname>Hyun</surname> 
                     <given-names>SH</given-names>
                  </name>, <name>
                     <surname>Jeung</surname> 
                     <given-names>EB</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells</article-title>. <source>Cancer Gene Ther</source>. <year>2012</year> 
               <month>Aug</month>;<volume>19</volume>(<issue>8</issue>):<fpage>517</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/cgt.2012.30</pub-id>
               <pub-id pub-id-type="pmid">22653384</pub-id>
               <issn>0929-1903</issn>
            </mixed-citation>
         </ref>
         <ref id="b42">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Paeini-Vayghan</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Peirovi</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Niknejad</surname> 
                     <given-names>H</given-names>
                  </name>
               </person-group>. <article-title>Inducing of angiogenesis is the net effect of the amniotic membrane without epithelial cells</article-title>. <source>Irn J Med Hypotheses Ideas.</source> 
               <year>2011</year>;<volume>5</volume>:<fpage>16</fpage>–<lpage>21</lpage>.</mixed-citation>
         </ref>
         <ref id="b43">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Vander Heiden</surname> 
                     <given-names>MG</given-names>
                  </name>, <name>
                     <surname>Cantley</surname> 
                     <given-names>LC</given-names>
                  </name>, <name>
                     <surname>Thompson</surname> 
                     <given-names>CB</given-names>
                  </name>
               </person-group>. <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source>Science</source>. <year>2009</year> 
               <month>May</month>;<volume>324</volume>(<issue>5930</issue>):<fpage>1029</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1126/science.1160809</pub-id>
               <pub-id pub-id-type="pmid">19460998</pub-id>
               <issn>0036-8075</issn>
            </mixed-citation>
         </ref>
         <ref id="b44">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Cairns</surname> 
                     <given-names>RA</given-names>
                  </name>, <name>
                     <surname>Harris</surname> 
                     <given-names>IS</given-names>
                  </name>, <name>
                     <surname>Mak</surname> 
                     <given-names>TW</given-names>
                  </name>
               </person-group>. <article-title>Regulation of cancer cell metabolism</article-title>. <source>Nat Rev Cancer</source>. <year>2011</year> 
               <month>Feb</month>;<volume>11</volume>(<issue>2</issue>):<fpage>85</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2981</pub-id>
               <pub-id pub-id-type="pmid">21258394</pub-id>
               <issn>1474-175X</issn>
            </mixed-citation>
         </ref>
         <ref id="b45">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Mamede</surname> 
                     <given-names>AC</given-names>
                  </name>, <name>
                     <surname>Laranjo</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Carvalho</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Abrantes</surname> 
                     <given-names>AM</given-names>
                  </name>, <name>
                     <surname>Pires</surname> 
                     <given-names>AS</given-names>
                  </name>, <name>
                     <surname>Brito</surname> 
                     <given-names>AF</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study</article-title>. <source>J Membr Biol</source>. <year>2014</year> 
               <month>Apr</month>;<volume>247</volume>(<issue>4</issue>):<fpage>357</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s00232-014-9642-3</pub-id>
               <pub-id pub-id-type="pmid">24577414</pub-id>
               <issn>0022-2631</issn>
            </mixed-citation>
         </ref>
         <ref id="b46">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Mittal</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Gubin</surname> 
                     <given-names>MM</given-names>
                  </name>, <name>
                     <surname>Schreiber</surname> 
                     <given-names>RD</given-names>
                  </name>, <name>
                     <surname>Smyth</surname> 
                     <given-names>MJ</given-names>
                  </name>
               </person-group>. <article-title>New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape</article-title>. <source>Curr Opin Immunol</source>. <year>2014</year> 
               <month>Apr</month>;<volume>27</volume>:<fpage>16</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2014.01.004</pub-id>
               <pub-id pub-id-type="pmid">24531241</pub-id>
               <issn>0952-7915</issn>
            </mixed-citation>
         </ref>
         <ref id="b47">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Grivennikov</surname> 
                     <given-names>SI</given-names>
                  </name>, <name>
                     <surname>Greten</surname> 
                     <given-names>FR</given-names>
                  </name>, <name>
                     <surname>Karin</surname> 
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Immunity, inflammation, and cancer</article-title>. <source>Cell</source>. <year>2010</year> 
               <month>Mar</month>;<volume>140</volume>(<issue>6</issue>):<fpage>883</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.01.025</pub-id>
               <pub-id pub-id-type="pmid">20303878</pub-id>
               <issn>0092-8674</issn>
            </mixed-citation>
         </ref>
         <ref id="b48">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Roelen</surname> 
                     <given-names>DL</given-names>
                  </name>, <name>
                     <surname>van der Mast</surname> 
                     <given-names>BJ</given-names>
                  </name>, <name>
                     <surname>in’t Anker</surname> 
                     <given-names>PS</given-names>
                  </name>, <name>
                     <surname>Kleijburg</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Eikmans</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>van Beelen</surname> 
                     <given-names>E</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells</article-title>. <source>Hum Immunol</source>. <year>2009</year> 
               <month>Jan</month>;<volume>70</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2008.10.016</pub-id>
               <pub-id pub-id-type="pmid">19010366</pub-id>
               <issn>0198-8859</issn>
            </mixed-citation>
         </ref>
         <ref id="b49">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Chang</surname> 
                     <given-names>CJ</given-names>
                  </name>, <name>
                     <surname>Yen</surname> 
                     <given-names>ML</given-names>
                  </name>, <name>
                     <surname>Chen</surname> 
                     <given-names>YC</given-names>
                  </name>, <name>
                     <surname>Chien</surname> 
                     <given-names>CC</given-names>
                  </name>, <name>
                     <surname>Huang</surname> 
                     <given-names>HI</given-names>
                  </name>, <name>
                     <surname>Bai</surname> 
                     <given-names>CH</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma</article-title>. <source>Stem Cells</source>. <year>2006</year> 
               <month>Nov</month>;<volume>24</volume>(<issue>11</issue>):<fpage>2466</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1634/stemcells.2006-0071</pub-id>
               <pub-id pub-id-type="pmid">17071860</pub-id>
               <issn>1066-5099</issn>
            </mixed-citation>
         </ref>
         <ref id="b50">
            <mixed-citation publication-type="unknown" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Banas</surname> 
                     <given-names>RA</given-names>
                  </name>, <name>
                     <surname>Trumpower</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Bentlejewski</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Marshall</surname> 
                     <given-names>V</given-names>
                  </name>, <name>
                     <surname>Sing</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Zeevi</surname> 
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells.</article-title> Hum Immunol. <year>2008</year>;69(6)-321–8.</mixed-citation>
         </ref>
         <ref id="b51">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Waugh</surname> 
                     <given-names>DJ</given-names>
                  </name>, <name>
                     <surname>Wilson</surname> 
                     <given-names>C</given-names>
                  </name>
               </person-group>. <article-title>The interleukin-8 pathway in cancer</article-title>. <source>Clin Cancer Res</source>. <year>2008</year> 
               <month>Nov</month>;<volume>14</volume>(<issue>21</issue>):<fpage>6735</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4843</pub-id>
               <pub-id pub-id-type="pmid">18980965</pub-id>
               <issn>1078-0432</issn>
            </mixed-citation>
         </ref>
         <ref id="b52">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>De Larco</surname> 
                     <given-names>JE</given-names>
                  </name>, <name>
                     <surname>Wuertz</surname> 
                     <given-names>BR</given-names>
                  </name>, <name>
                     <surname>Furcht</surname> 
                     <given-names>LT</given-names>
                  </name>
               </person-group>. <article-title>The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8</article-title>. <source>Clin Cancer Res</source>. <year>2004</year> 
               <month>Aug</month>;<volume>10</volume>(<issue>15</issue>):<fpage>4895</fpage>–<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0760</pub-id>
               <pub-id pub-id-type="pmid">15297389</pub-id>
               <issn>1078-0432</issn>
            </mixed-citation>
         </ref>
         <ref id="b53">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Takamori</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Oades</surname> 
                     <given-names>ZG</given-names>
                  </name>, <name>
                     <surname>Hoch</surname> 
                     <given-names>OC</given-names>
                  </name>, <name>
                     <surname>Burger</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Schraufstatter</surname> 
                     <given-names>IU</given-names>
                  </name>
               </person-group>. <article-title>Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1</article-title>. <source>Pancreas</source>. <year>2000</year> 
               <month>Jul</month>;<volume>21</volume>(<issue>1</issue>):<fpage>52</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/00006676-200007000-00051</pub-id>
               <pub-id pub-id-type="pmid">10881932</pub-id>
               <issn>0885-3177</issn>
            </mixed-citation>
         </ref>
         <ref id="b54">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lang</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Niggemann</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Zanker</surname> 
                     <given-names>KS</given-names>
                  </name>, <name>
                     <surname>Entschladen</surname> 
                     <given-names>F</given-names>
                  </name>
               </person-group>. <article-title>Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop</article-title>. <source>Int J Cancer</source>. <year>2002</year> 
               <month>Jun</month>;<volume>99</volume>(<issue>5</issue>):<fpage>673</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.10424</pub-id>
               <pub-id pub-id-type="pmid">12115500</pub-id>
               <issn>0020-7136</issn>
            </mixed-citation>
         </ref>
         <ref id="b55">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Yao</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Lin</surname> 
                     <given-names>Y</given-names>
                  </name>, <name>
                     <surname>Chua</surname> 
                     <given-names>MS</given-names>
                  </name>, <name>
                     <surname>Ye</surname> 
                     <given-names>CS</given-names>
                  </name>, <name>
                     <surname>Bi</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Li</surname> 
                     <given-names>W</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells</article-title>. <source>Int J Cancer</source>. <year>2007</year> 
               <month>Nov</month>;<volume>121</volume>(<issue>9</issue>):<fpage>1949</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.22930</pub-id>
               <pub-id pub-id-type="pmid">17621625</pub-id>
               <issn>0020-7136</issn>
            </mixed-citation>
         </ref>
         <ref id="b56">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Maxwell</surname> 
                     <given-names>PJ</given-names>
                  </name>, <name>
                     <surname>Gallagher</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Seaton</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Wilson</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Scullin</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Pettigrew</surname> 
                     <given-names>J</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells</article-title>. <source>Oncogene</source>. <year>2007</year> 
               <month>Nov</month>;<volume>26</volume>(<issue>52</issue>):<fpage>7333</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1210536</pub-id>
               <pub-id pub-id-type="pmid">17533374</pub-id>
               <issn>0950-9232</issn>
            </mixed-citation>
         </ref>
         <ref id="b57">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Magatti</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Caruso</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>De Munari</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Vertua</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>De</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Manuelpillai</surname> 
                     <given-names>U</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Human Amniotic Membrane-Derived Mesenchymal and Epithelial Cells Exert Different Effects on Monocyte-Derived Dendritic Cell Differentiation and Function</article-title>. <source>Cell Transplant</source>. <year>2015</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1733</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.3727/096368914X684033</pub-id>
               <pub-id pub-id-type="pmid">25259480</pub-id>
               <issn>0963-6897</issn>
            </mixed-citation>
         </ref>
         <ref id="b58">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Li</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Niederkorn</surname> 
                     <given-names>JY</given-names>
                  </name>, <name>
                     <surname>Neelam</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Mayhew</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Word</surname> 
                     <given-names>RA</given-names>
                  </name>, <name>
                     <surname>McCulley</surname> 
                     <given-names>JP</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Immunosuppressive factors secreted by human amniotic epithelial cells</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2005</year> 
               <month>Mar</month>;<volume>46</volume>(<issue>3</issue>):<fpage>900</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.04-0495</pub-id>
               <pub-id pub-id-type="pmid">15728546</pub-id>
               <issn>0146-0404</issn>
            </mixed-citation>
         </ref>
         <ref id="b59">
            <mixed-citation publication-type="web-page" specific-use="unparsed">
               <person-group person-group-type="author">
                  <collab>U.S. National Institutes of Health</collab>
               </person-group>. Clinical Trials. U.S. Bethesda: National Library of Medicine; <year>2017</year> [cited 2018 Feb 26]. Dostopno: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>
            </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
